The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

Please consult the full Prescribing Information for additional ... those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q4 Results for ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

GSK has teamed up with the University ... changes in cells in precancerous stages that could form the basis of vaccines to prevent full-blown cancer from developing. The pharma group has pledged ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare ... has moved to take full control of the CAR-T ...

Harvey Jones had high hopes for the Unilever share price but once again, it's going backwards. Should he sell the FTSE 100 stock or simply ignore it?

US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...

The E.W. Scripps Company has entered into a transaction support agreement (TSA) with lenders representing more than 70% of the aggregate principal amount of Scripps' outstanding tranche B-2 term loans ...

Obesity is a chronic disease affecting 42% of adults over age 60 in the U.S. Yet Medicare is not allowed to cover the full spectrum of ... today whether to approve GSK’s vaccine candidate ...